On June 2, 2024, GSK plc announced that their Blenrep treatment reduced the risk of disease progression in relapsed/refractory multiple myeloma by nearly 50%, with a median progression-free survival of not yet reached at 21.8 months compared to 12.7 months for standard treatment.